(Q53534282)

English

Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure.

scientific article published in January 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

0 references

1 reference

based on heuristic

chronic heart failure

1 reference

based on heuristic

2

object named as

R M Califf

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

author name string

M S Cuffe

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

K F Adams

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

R C Bourge

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

W Colucci

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

B Massie

6

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

C M O'Connor

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

I Pina

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

R Quigg

9

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

M Silver

10

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

L A Robinson

11

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

J D Leimberger

12

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

M Gheorghiade

13

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

language of work or name

0 references

publication date

1 January 2000

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

139

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

1 Pt 1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

15-22

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

The epidemiology of heart failure: the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Prevalence and mortality rate of congestive heart failure in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Effect of DRGs on three-month readmission rate of geriatric patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Early readmission of elderly patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Medical conditions differentially affect the development of IADL disability: implications for medical care and research

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Milrinone: basic and clinical pharmacology and acute and chronic management

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Current medical therapy for advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Reporting Bayesian analyses of clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

The hibernating myocardium: implications for management of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Identifiers

10.1016/S0002-8703(00)90303-X

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53534282&oldid=2067428754"